Article

AAX Biotech has announced an investment from Trio Impact Invest AB to further develop and scale its antibody technology platforms. This funding aims to enhance platform capabilities and foster industry collaborations, following the company's progress in automation and partnerships, notably with Daiichi Sankyo. The investment will focus on advancing the platforms and building on existing partnerships, marking a significant step in AAX Biotech's growth strategy.